Eteplirsen approved for Duchenne muscular dystrophy

被引：6
|
作者：
Traynor, Kate
机构：
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2016年 / 73卷 / 21期
关键词：
D O I：
10.2146/news160063
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1719 / 1719
页数：1
相关论文
共 50 条
  • [21] Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study
    Iff, Joel
    Carmichael, Chloe
    McKee, Stephanie
    Sehinovych, Ihor
    McNeill, Carolyn
    Tesi-Rocha, Carolina
    Henricson, Erik
    Muntoni, Francesco
    Kitchen, Helen
    [J]. ADVANCES IN THERAPY, 2024, 41 (08) : 3278 - 3298
  • [22] First Drug to Treat Duchenne Muscular Dystrophy Approved
    不详
    [J]. US PHARMACIST, 2016, 41 (10)
  • [23] Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
    Alfano, Lindsay N.
    Charleston, Jay S.
    Connolly, Anne M.
    Cripe, Linda
    Donoghue, Cas
    Dracker, Robert
    Dworzak, Johannes
    Eliopoulos, Helen
    Frank, Diane E.
    Lewis, Sarah
    Lucas, Karin
    Lynch, Jessie
    Milici, A. J.
    Flynt, Amy
    Naughton, Emily
    Rodino-Klapac, Louise R.
    Sahenk, Zarife
    Schnell, Frederick J.
    Young, G. David
    Mendell, Jerry R.
    Lowes, Linda P.
    [J]. MEDICINE, 2019, 98 (26) : e15858
  • [24] Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
    Mendell, Jerry R.
    Goemans, Nathalie
    Lowes, Linda P.
    Alfano, Lindsay N.
    Berry, Katherine
    Shao, James
    Kaye, Edward M.
    Mercuri, Eugenio
    Hamid, Hoda Abdel
    Byrne, Barry J.
    Connolly, Anne M.
    Dracker, Robert A.
    Frank, L. Matthew
    Heydemann, Peter T.
    O'Brien, Kevin C.
    Sparks, Susan E.
    Specht, Linda A.
    Rodino-Klapac, Louise
    Sahenk, Zarife
    Al-Zaidy, Samiah
    Cripe, Linda H.
    Lewis, Sarah
    Pane, M.
    Mazzone, E.
    Messina, Sonia
    Vita, G. L.
    D'Amico, A.
    Bertini, E. S.
    Berardinelli, A.
    Torrente, Y.
    Magri, F.
    Comi, G. P.
    Baranello, G.
    Mongini, T.
    Pini, A.
    Battini, R.
    Pegoraro, E.
    Bruno, C.
    Politano, L.
    Previtali, S.
    [J]. ANNALS OF NEUROLOGY, 2016, 79 (02) : 257 - 271
  • [25] Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for the Treatment of Duchenne Muscular Dystrophy (DMD)
    Kaye, E. M.
    Mendell, J. R.
    Rodino-Klapac, L.
    Sahenk, Z.
    Lowes, L. P.
    Alfano, L. N.
    Berry, K.
    Gomez, A. M.
    Lewis, S.
    Flanigan, K. M.
    Cripe, L. H.
    Al-Zaidy, S.
    Duda, P. W.
    Saoud, J. B.
    [J]. ANNALS OF NEUROLOGY, 2015, 78 : S105 - S105
  • [26] Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy
    Iff, Joel
    Gerrits, Charles
    Zhong, Yi
    Tuttle, Edward
    Birk, Erica
    Zheng, Yeya
    Paul, Xander
    Henricson, Erik K.
    McDonald, Craig M.
    [J]. MUSCLE & NERVE, 2022, 66 (03) : 262 - 269
  • [27] Tolerability of Eteplirsen for Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy
    Bhalla, Sonam
    Lakhotia, Arpita
    [J]. NEUROLOGY, 2018, 90
  • [28] Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative Viewpoint
    Irwin, Adriane N.
    Herink, Megan C.
    [J]. PHARMACOTHERAPY, 2017, 37 (10): : E109 - E111
  • [29] Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical Update
    Mendell, J. R.
    Rodino-Klapac, L.
    Sahenk, Z.
    Lowes, L. P.
    Alfano, L. N.
    Berry, K.
    Gomez-Ramirez, A. M.
    Lewis, S.
    Flanigan, K. M.
    Cripe, L.
    Al-Zaidy, S.
    Duda, P.
    Sazani, P.
    Saoud, J.
    Kaye, E. M.
    [J]. ANNALS OF NEUROLOGY, 2015, 78 : S212 - S212
  • [30] Survival in eteplirsen-treated Duchenne Muscular Dystrophy patients: Are there benefits beyond steroids?
    Burnette, W. Bryan
    [J]. MUSCLE & NERVE, 2024, 70 (01) : 4 - 5
12345